Mesoblast shares savaged on poor trial results for COVID treatment

Mesoblast chief executive Silviu Itescu. The company was hoping to show its flagship product, remestemcel-L, would help patients with moderate to severe respiratory distress because of coronavirus.CREDIT:CREDIT: ARSINEH HOUSPIAN https://www.smh.com.au/business/companies/mesoblast-shares-savaged-on-poor-covid-trial-results-20201218-p56onp.html

Rate this:

Read Article →

Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai

John Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. Photo by Cedars-Sinai https://www.newswise.com/articles/hematologiststem-cell-biologist-to-direct-hematology-and-cellular-therapy-at-cedars-sinai

Rate this:

Read Article →

Study Shows No Increased Frequency of Cancer-Causing Mutations in Naïve Pluripotent Stem Cells

Human embryonic stem cell colonies that have been stained for alkaline phosphatase (red). Credit: Yuhuan Wang, Cell Image Library https://www.technologynetworks.com/cell-science/news/study-shows-no-increased-frequency-of-cancer-causing-mutations-in-nave-pluripotent-stem-cells-343957

Rate this:

Read Article →

Researchers develop new system to conduct accurate telomere profiling in less than 3 hours

A magnified image captured by the device used to perform STAR assay. Different fluorescent intensities reflect the length variations in individual telomere molecules. Credit: National University of Singapore https://phys.org/news/2020-08-accurate-telomere-profiling-hours.html

Rate this:

Read Article →